Effect of predelivery diagnosis in 99 consecutive cases of placenta accreta
- PMID: 20027036
- DOI: 10.1097/AOG.0b013e3181c4f12a
Effect of predelivery diagnosis in 99 consecutive cases of placenta accreta
Abstract
Objective: To estimate the effects of prenatal diagnosis and delivery planning on outcomes in patients with placenta accreta.
Methods: A review was performed of all patients with pathologically confirmed placenta accreta at the University of California, San Diego Medical Center from January 1990 to April 2008. Cases were divided into those with and without predelivery diagnosis of placenta accreta. Patients with prenatal diagnosis of placenta accreta were scheduled for planned en bloc hysterectomy without removal of the placenta at 34-35 weeks of gestation after betamethasone administration. Maternal and neonatal outcomes were assessed.
Results: Ninety-nine women with placenta accreta were identified, of whom 62 were diagnosed before delivery and 37 were diagnosed intrapartum. Comparing women with predelivery diagnosis with those diagnosed at the time of delivery, there were fewer units of packed red blood cells transfused (4.7+/-2.2 compared with 6.9+/-1.8 units, P=.02) and a lower estimated blood loss (2,344+/-1.7 compared with 2,951+/-1.8 mL, P=.053), although this trend did not reach statistical significance. Comparison of neonatal outcomes demonstrated a higher rate of steroid administration (65% compared with 16%, P<or=.001), neonatal admission to the neonatal intensive care unit (NICU) (86% compared with 60%, P=.005), and longer neonatal hospital stays (10.7+/-1.9 compared with 6.9+/-2.1 days, P=.006). Length of NICU stay, rates of respiratory distress syndrome, and surfactant administration did not differ between the groups.
Conclusion: Predelivery diagnosis of placenta accreta is associated with decreased maternal hemorrhagic morbidity. Planned delivery at 34-35 weeks of gestation in this cohort did not significantly increase neonatal morbidity.
Level of evidence: II.
Similar articles
-
Placenta Accreta Spectrum Treatment With Intraoperative Multivessel Embolization: the PASTIME protocol.Am J Obstet Gynecol. 2021 Oct;225(4):442.e1-442.e10. doi: 10.1016/j.ajog.2021.07.001. Epub 2021 Jul 7. Am J Obstet Gynecol. 2021. PMID: 34245679
-
Emergency delivery in pregnancies at high probability of placenta accreta spectrum on prenatal imaging: a systematic review and meta-analysis.Am J Obstet Gynecol MFM. 2024 Oct;6(10):101432. doi: 10.1016/j.ajogmf.2024.101432. Epub 2024 Jul 26. Am J Obstet Gynecol MFM. 2024. PMID: 39069207
-
Placenta percreta is associated with more frequent severe maternal morbidity than placenta accreta.Am J Obstet Gynecol. 2018 Aug;219(2):193.e1-193.e9. doi: 10.1016/j.ajog.2018.04.049. Epub 2018 May 5. Am J Obstet Gynecol. 2018. PMID: 29733839
-
Antenatal diagnosis of placenta accreta leads to reduced blood loss.Acta Obstet Gynecol Scand. 2011 Oct;90(10):1140-6. doi: 10.1111/j.1600-0412.2011.01147.x. Epub 2011 May 25. Acta Obstet Gynecol Scand. 2011. PMID: 21488840
-
Placenta accreta and the risk of adverse maternal and neonatal outcomes.J Perinat Med. 2013 Mar;41(2):141-9. doi: 10.1515/jpm-2012-0219. J Perinat Med. 2013. PMID: 23241664 Review.
Cited by
-
Hemorrhagic morbidity in placenta accreta spectrum with and without placenta previa.Arch Gynecol Obstet. 2019 Dec;300(6):1601-1606. doi: 10.1007/s00404-019-05338-y. Epub 2019 Nov 5. Arch Gynecol Obstet. 2019. PMID: 31691015 Free PMC article.
-
Association of Placenta Previa With Severe Maternal Morbidity Among Patients With Placenta Accreta Spectrum Disorder.JAMA Netw Open. 2022 Aug 1;5(8):e2228002. doi: 10.1001/jamanetworkopen.2022.28002. JAMA Netw Open. 2022. PMID: 35994286 Free PMC article.
-
Maternal Serum Screening Markers and Adverse Outcome: A New Perspective.J Clin Med. 2014 Jul 3;3(3):693-712. doi: 10.3390/jcm3030693. J Clin Med. 2014. PMID: 26237472 Free PMC article. Review.
-
The role of ultrasound in prediction of intra-operative blood loss in cases of placenta accreta spectrum disorders.Arch Gynecol Obstet. 2020 Nov;302(5):1143-1150. doi: 10.1007/s00404-020-05707-y. Epub 2020 Aug 1. Arch Gynecol Obstet. 2020. PMID: 32740869
-
Cesarean Hysterectomy in Abnormally Invasive Placenta: The Role of Prenatal Diagnosis.Diseases. 2021 Aug 17;9(3):56. doi: 10.3390/diseases9030056. Diseases. 2021. PMID: 34449610 Free PMC article.
References
-
- Hamilton BE, Martin JA, Ventura SJ, Sutton PD, Menacker F. Births: preliminary data for 2004. Natl Vital Stat Rep 2005;54:1–17.
-
- Hudon L, Belfort MA, Broome DR. Diagnosis and management of placenta percreta: a review. Obstet Gynecol Surv 1998;53:509–17.
-
- O’Brien JM, Barton JR, Donaldson ES. The management of placenta percreta: conservative and operative strategies. Am J Obstet Gynecol 1996;175:1632–8.
-
- Miller DA, Chollet JA, Goodwin TM. Clinical risk factors for placenta previa-placenta accreta. Am J Obstet Gynecol 1997;177:210–4.
-
- Clark SL, Koonings PP, Phelan JP. Placenta previa/accreta and prior cesarean section. Obstet Gynecol 1985;66:89–92.
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous